Alzheimer’s Disease
-
Beckman Coulter secures EU CE mark for Access p-Tau217 Alzheimer’s blood test
The approval allows laboratories across Europe and other CE-recognising markets to use the assay to support the clinical evaluation of amyloid pathology in people showing signs of cognitive decline.
-
QuantumCell inks US$2.2B Alzheimer’s deal with AlzeCure Pharma
Under the agreement, QuantumCell will obtain global rights to AlzeCure’s NeuroRestore platform, including its lead drug candidate, ACD856.
-
Eli Lilly signs US$1B Alzheimer’s deal with AlzeCure Pharma for ACD680
The partnership grants Lilly global rights to AlzeCure’s preclinical small-molecule candidate, ACD680, which targets the biology of Alzheimer’s disease.
-
Mayo Clinic identifies key DNA changes driving Alzheimer’s patient variability
Researchers found that nearly all major DNA methylation changes were associated with tau accumulation rather than amyloid plaques.
-
Mayo Clinic Study links alpha-synuclein protein to faster Alzheimer’s progression in women
Alzheimer’s disease is characterized by the accumulation of tau protein in the brain, which gradually damages nerve cells and impairs memory and cognitive function.
-
Metabolic collaborates with Roche to establish early Alzheimer’s screening research initiative in Dubai
Researchers aim to assess the reliability of p-Tau217 in identifying early Alzheimer’s pathology and evaluate its potential as a scalable tool for long-term monitoring.
-
Mayo Clinic develops breakthrough tool to predict Alzheimer’s risk years before symptoms appear
The study revealed that women face a higher lifetime risk than men of developing dementia and mild cognitive impairment (MCI), a transitional stage between healthy aging and dementia.
-
Siemens Healthineers to co-lead major EU Initiative advancing Alzheimer’s disease diagnosis and treatment
The ACCESS-AD project launches in January 2026 with an ambitious goal to establish a collaborative, patient-centered approach to Alzheimer’s care throughout Europe.